AIDS ASSOCIATED MALIGNANCIES CLINICAL TRIALS CONSORTIUM

艾滋病恶性肿瘤是发病率和死亡率不断上升的原因 艾滋病病毒感染者。 例如，在ACTG 019试验中 在协和试验中，恶性肿瘤占25%以上， 在这些无症状的HIV感染人群中的研究终点。 在 ACTG 196试验，在非常晚期患者中进行的试验，恶性肿瘤占 造成了超过23%的死亡 显然，随着艾滋病病毒感染者的生活 时间越长，恶性并发症将变得越频繁， 毁灭性的 幸运的是，我们在理解 几种艾滋病相关恶性肿瘤的发病机制。 改进的基本 科学认识为药物开发提供了许多新的线索。 据推测，系统评价多种新的 治疗机会将导致显著增加， 艾滋病毒感染者的预期寿命。 加州大学洛杉矶分校一直处于抗击艾滋病的前沿， 恶性并发症 加州大学洛杉矶分校是最早发现 诊所，并继续拥有最大的卡波西肉瘤诊所之一， 世界 加州大学洛杉矶分校的基础科学家为我们的研究做出了重大贡献。 了解这种疾病和艾滋病相关的淋巴瘤。 的临床医生 加州大学洛杉矶分校设计、招募并完成了许多重要的艾滋病试验 相关的恶性肿瘤。 加州大学洛杉矶分校的调查人员有一个特殊的专业知识 在细胞因子和免疫调节剂的使用中。 本申请建议利用两个人的综合才能 在艾滋病治疗方面具有丰富经验的研究人员 恶性肿瘤。 它将利用我们在合作方面的经验 小组试验，如艾滋病临床试验小组。 它还将使用 位于加州大学洛杉矶分校的艾滋病储蓄银行。 加州大学洛杉矶分校的贡献 艾滋病临床试验联盟的整体努力将 促进我们对这些疾病的理解和治疗。

AIDS malignancies represent an increasing cause of morbidity and mortality for persons with HIV infection. For example, in both the ACTG 019 trial and in the Concorde trial, malignancies accounted for over 25% of the study endpoints in these asymptomatic, HIV infected populations. In the ACTG 196 trial, a trial in very advanced patients, malignancies accounted for over 23% of the deaths. Clearly, as patients with HIV infection live longer, malignant complications will become more frequent and more devastating. Fortunately, there has been substantial progress in our understanding of the pathogenesis of several AIDS related malignancies. The improved basic science understanding has provided many new leads for drug development. It is hypothesized that a systematic evaluation of the multiple new therapeutic opportunities will result in a significant increase in the life expectancy for patients with HIV infection. UCLA has been at the fore front in the battle against AIDS and its malignant complications. UCLA was one of the first to have a malignancy clinic and continues to have one of the largest Kaposi sarcoma clinics in the world. Basic scientists at UCLA have contributed significantly to our understanding of this disease and AIDS related lymphomas. Clinicians at UCLA have designed, enrolled and completed many important trials in AIDS related malignancies. Investigators at UCLA have a particular expertise in the use of cytokines and immune modulators. This application proposes to utilize the combined talents of two investigators with an extensive experience in the treatment of AIDS malignancies. It will take advantage of our experience in cooperative group trials such as the AIDS Clinical Trials Group. It will also use the AIDS Malignancy Bank that is located at UCLA. The contribution of UCLA to the overall effort of the AIDS Malignancy Clinical Trials Consortium will advance our understanding and the treatment of these diseases.